GeneDx Holdings WGS Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price at other companies

Tarsus Pharmaceuticals, Inc.TARS

$47.13+56.3%

WaFd, Inc.WAFD

$7.53+36.9%

WSFS FinancialWSFS

$0.00-100%

MSCIMSCI

$665.73+16.9%

WSFS FinancialWSFS

$0.00-100%

The Travelers CompaniesTRV

$152.72+8.0%

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.89B-24.3%

Enterprise value$1.89B-22.8%

P/S4.3×-3.3×

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price?: GeneDx Holdings (WGS) reported share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price of $44.15 in Q1 2026.